Activation of the type i interferon pathway in primary Sjögren's syndrome: An update

Current Opinion in Rheumatology

Volumn 23, Issue 5, 2011, Pages 459-464

  Vakaloglou, Katerina M ^a   Mavragani, Clio P ^b  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

activation of type I interferon pathway; Sj gren's syndrome; systemic lupus erythematosus

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; ALPHA INTERFERON; BETA INTERFERON; BORTEZOMIB; CHEMOKINE RECEPTOR CXCR3; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; DOUBLE STRANDED RNA; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCOCORTICOID; IMMUNOGLOBULIN FC FRAGMENT; INTERFERON; INTERFERON REGULATORY FACTOR 5; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 1; INTERLEUKIN 5; MESSENGER RNA; STAT4 PROTEIN; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TRICHOSTATIN A; TUMOR NECROSIS FACTOR INHIBITOR;

CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE ASSOCIATION; DRUG TARGETING; ENTEROVIRUS; EPSTEIN BARR VIRUS; GENE DOSAGE; GENETIC POLYMORPHISM; GENETIC REGULATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; MACROPHAGE; ONCOGENE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIMARY SJOEGREN SYNDROME; PRIORITY JOURNAL; REVIEW; SALIVARY GLAND; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS;

HUMANS; IMMUNOMODULATION; INTERFERON TYPE I; POLYMORPHISM, GENETIC; SALIVARY GLANDS; SIGNAL TRANSDUCTION; SJOGREN'S SYNDROME;

EID: 80052025961     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328349fd30     Document Type: Review

References (55)

1. Mavragani CP, Crow MK. Activation of type I interferon pathway in primary Sjogren's syndrome. J Autoimmun 2010; 35:225-231.
2. Mancuso G, Gambuzza M, Midiri A, et al. Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells. Nat Immunol 2009; 10:587-594.
3. Poth JM, Coch C, Busch N, et al. Monocyte-mediated inhibition of TLR9-dependent IFN-( induction in plasmacytoid dendritic cells questions bacterial DNA as the active ingredient of bacterial lysates. J Immunol 2010; 185:7367-7373.
4. Makela SM, Osterlund P, Julkunen I. TLR ligands induce synergistic interferonb and interferon-l1 gene expression in human monocyte-derived dendritic cells. Mol Immunol 2011; 48:505-515.
5. Onoguchi K, Yoneyama M, Fujita T. Retinoic acid-inducible gene-I-like receptors. J Interferon Cytokine Res 2011; 31:27-31.
6. Mi Z, Fu J, Xiong Y, Tang H. SUMOylation of RIG-I positively regulates the type I interferon signaling. Protein Cell 2010; 1:275-283.
7. Choubey D, Duan X, Dickerson E, et al. Interferon-Inducible p200-family proteins as novel sensors of cytoplasmic DNA: role in inflammation and autoimmunity. J Interferon Cytokine Res 2010; 30:371-380.
8. Mondini M, Costa S, Sponza S, et al. The interferon-inducible HIN-200 gene family in apoptosis and inflammation: implication for autoimmunity. Autoimmunity 2010; 43:226-231.
9. Panchanathan R, Duan X, Shen H, et al. Aim2 deficiency stimulates the expression of IFN-inducible Ifi202, a lupus susceptibility murine gene within the Nba2 autoimmune susceptibility locus. J Immunol 2010; 185:7385-7393.
10. Fu J, Xiong Y, Xu Y, et al. MDA5 is SUMOylated by PIAS2b in the upregulation of type I interferon signaling. Mol Immunol 2011; 48:415-422.
11. Matsumiya T, Stafforini DM. Function and regulation of retinoic acid-inducible gene-I [review]. Crit Rev Immunol 2010; 30:489-513.
12. Li C, Ma L, Chen X. Interferon regulatory factor 3-CL, an isoform of IRF3, antagonizes activity of IRF3. Cell Mol Immunol 2010; 1:67-74.
13. Koop A, Lepenies I, Braum O, et al. Novel splice variants of human IKKe negatively regulate IKKe-induced IRF3 and NF-kB activation. Eur J Immunol 2011; 41:224-234.
14. Young JA, Sermwittayawong D, Kim HJ, et al. Fas-associated death domain (FADD) and the E3 ubiquitin-protein ligase TRIM21 interact to negatively regulate virus-induced interferon production. J Biol Chem 2011; 286:6521-6531.
15. Higgs R, Lazzari E, Wynne C, et al. Self protection from antiviral responses-Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral Toll-Like receptors. PLoS One 2010; 5:e11776.
16. Zhou H, Huang X, Cui H, et al. miR-155 and its star-form partner miR-155-cooperatively regulate type I interferon production by human plasmacytoid dendritic cells. Blood 2010; 116:5885-5894.
17. Zheng H, Qian J, Varghese B, et al. Ligand-stimulated downregulation of the alpha interferon receptor: role of protein kinase D2. Mol Cell Biol 2011; 31:710-720.
18. Lu J, Pan Q, Rong L, et al. The IFTM proteins inhibit HIV-1 infection. J Virol 2011; 85:2126-2137.
19. Zhang D, Zhang DE. Interferon-stimulated gene 15 and the protein ISGylation system. J Interferon Cytokine Res 2011; 31:119-130.
20. Liu SY, Sanchez DJ, Cheng G. New developments in the induction and antiviral effectors of type I interferon. Curr Opin Immunol 2011; 23:57-64.
21. Wang H, Brown J, Garcia CA, et al. The role of glycogen synthase kinase 3 in regulating IFN-b-mediated IL-10 production. J Immunol 2011; 186:675-684.
22. Badr G, Waly H, Eldien HM, et al. Blocking type I interferon (IFN) signaling impairs antigen responsiveness of circulating lymphocytes and alters their homing to lymphoid organs: protective role of type I IFN. Cell Physiol Biochem 2010; 26:1029-1040.
23. Arulampalam V, Kolosenko I, Hjortsberg L, et al. Activation of STAT1 is required for interferon-alpha-mediated cell death. Exp Cell Res 2011; 317:9-19.
24. Navarro F, Bacurau AV, Vanzelli A, et al. Changes in glucose and glutamine lymphocyte metabolisms induced by type I interferon a. Mediators Inflamm 2010; 2010:364290.
25. Mattei F, Schiavoni G, Tough DF. Regulation of immune cell homeostasis by type I interferons. Cytokine Growth Factor Rev 2010; 21:227-236.
26. Wiesel M, Kratky W, Oxenius A. Type I IFN substitutes for T cell help during viral infections. J Immunol 2011; 186:754-763.
27. Gregorio J, Meller S, Conrad C, et al. Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons. J Exp Med 2010; 207:2921-2930.
28. Denny MF, Thacker S, Mehta H, et al. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 2007; 110:2907-2915. (Pubitemid 350006944)
29. Li J, Fu Q, Cui H, et al. Interferon-a priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-a and atherosclerosis in lupus. Arthritis Rheum 2011; 63:492-502.
30. Thacker SG, Berthier CC, Mattinzoli D, et al. The detrimental effects of IFN-a on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. J Immunol 2010; 185:4457-4469.
31. Park K, Scott AL. Cholesterol 25-hydroxylase production by dendritic cells and macrophages is regulated by type I interferons. J Leukoc Biol 2010; 88:1081-1087.
32. Yuan W, DiMartino SJ, Redecha PB, et al. Systemic lupus erythematosus monocytes are less responsive to interleukin-10 in the presence of immune complexes. Arthritis Rheum 2011; 63:212-218.
33. Sozzani S, Bosisio D, Scarsi M, Tincani A. Type I interferons in systemic autoimmunity. Autoimmunity 2010; 43:196-203.
34. Weckerle CE, Franek BS, Kelly JA, et al. Network analysis of associations between interferon alpha activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum 2011; 63:1044-1053.
35. Ittah M,Miceli-Richard C, Lebon P, et al. Induction of B cell-activating factor by viral infection is a general phenomenon, but the types of viruses and mechanisms depend on cell type. J Innate Immun 2011; 3:200-207.
36. Costa S, Borgogna C, Mondini M, et al. Redistribution of the nuclear protein IFI16 into the cytoplasm of ultraviolet B-exposed keratinocytes as a mechanism of autoantigen processing. Br J Dermatol 2011; 164:282-290.
37. Hooks JJ, Moutsopoulos HM, Geis SA, et al. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979; 301:5-8. (Pubitemid 9226519)
38. Niewold TB, Rivera TL, Buyon JP, Crow MK. Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus. Arthritis Rheum 2008; 58:541-546. (Pubitemid 351294888)
39. Mavragani CP, Niewold TB, Moutsopoulos NM, et al. Augmented interferon-a pathway activation in patients with Sjogren's syndrome treated with etanercept. Arthritis Rheum 2007; 56:3995-4004. (Pubitemid 350262327)
40. Li Y, Lee PY, Kellner ES, et al. Monocyte surface expression of Fcgamma receptor RI (CD64), a biomarker reflecting type-I interferon levels in systemic lupus erythematosus. Arthritis Res Ther 2010; 12:R90. A novel study suggesting that determination of CD64 monocyte expression by flow cytometric analysis can accurately reflect peripheral type I IFN activity.
41. Coccia EM. IFN regulation and functions in myeloid dendritic cells. Cytokine Growth Factor Rev 2008; 19:21-32. (Pubitemid 351200061)
42. Reizis B, Bunin A, Ghosh HS, et al. Plasmacytoid Dendritic Cells: recent progress and open questions. Annu Rev Immunol 2011; 29:163-183.
43. Lande R, Gilliet M. Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses. Ann N Y Acad Sci 2010; 1183:89-103. A comprehensive review of the contributory role of PDCs in generation and regulation of immune responses.
44. Katashiba Y, Miyamoto R, Hyo A, et al. Interferon-a and interleukin-12 are induced, respectively, by double-stranded DNA and single-stranded RNA in human myeloid dendritic cells. Immunology 2011; 132:165-173.
45. Sandling JK, Garnier S, Sigurdsson S, et al. A candidate gene study of the type I interferon pathway implicates IKBKE and IL8 as risk loci for SLE. Eur J Hum Genet 2011; 19:479-484.
46. Hikami K, Kawasaki A, Ito I, et al. Association of a functional polymorphism in the 3' untranslated region of SPI1 with systemic lupus erythematosus. Arthritis Rheum 2011; 63:755-763.
47. Harley IT, Niewold TB, Stormont RM, et al. The role of genetic variation near interferon-kappa in systemic lupus erythematosus. J Biomed Biotechnol 2010; 2010:706825.
48. Kariuki SN, Franek BS, Mikolaitis RA, et al. Promoter variant of PIK3C3 is associated with autoimmunity against Ro and Sm epitopes in African-American lupus patients. J Biomed Biotechnol 2010; 2010:826434.
49. Garća-OrtizH,Velázquez-CruzR,Espinosa-Rosales F,et al.AssociationofTLR7 copy number variation with susceptibility to childhood-onset systemic lupus erythematosus in Mexican population. Ann Rheum Dis 2010; 69:1861-1865.
50. Gestermann N, Mekinian A, Comets E, et al. STAT4 is a confirmed genetic risk factor for Sjö gren's syndrome and could be involved in type 1 interferon pathway signaling. Genes Immun 2010; 11:432-438.
51. Flammer JR, Dobrovolna J, Kennedy MA, et al. The type I interferon signaling pathway is a target for glucocorticoid inhibition. Mol Cell Biol 2010; 19:4564-4574.
52. Amuro H, Ito T, Miyamoto R, et al. Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, function as inhibitors of cellular and molecular components involved in type I interferon production. Arthritis Rheum 2010; 62:2073-2085.
53. Salvi V, Bosisio D, Mitola S, et al. Trichostatin A blocks type I interferon production by activated plasmacytoid dendritic cells. Immunobiology 2010; 215:756-761.
54. Miyamoto R, Ito T, Nomura S, et al. Inhibitor of IkappaB kinase activity, BAY 11-7082, interferes with interferon regulatory factor 7 nuclear translocation and type I interferon production by plasmacytoid dendritic cells. Arthritis Res Ther 2010; 12:R87.
55. Hirai M, Kadowaki N, Kitawaki T, et al. Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis. Blood 2011; 117:500-509.